Ocular Therapeutix Inc

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives. With a focus on advancing our products through to Phase 3 clinical trials, our intention is to develop a commercially viable portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing for better patient outcomes.

Ocular Therapeutix hydrogel technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions. The hydrogel delivery technology enables creation of sustained release dosage forms of drugs that have been previously approved by the FDA when formulated as drops or injections. The hydrogel is a biodegradable polyethylene glycol (PEG) network and is preservative free. This hydrogel network is a meshwork that entraps the drug particles. When administered, the PEG network hydrates with water, then the drug particles begin to dissolve, diffusing the drug outward from the hydrogel into the surrounding local tissues. Following the completion of drug delivery, the hydrogel biodegrades and is cleared from the body.